Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status

다국어 초록 (Multilingual Abstract)

Objective: To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression.
Methods: We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry.
Results: Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01).
Conclusion: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.

참고문헌 (Reference)

1 Development Core Team, "a language and environment for statistical computing" R Foundation for Statistical Computing 2004

2 Rosen DG., "Validation of tissue microarray technology in ovarian carcinoma" 17 : 790-797, 2004

3 Slotman BJ., "Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator" 66 : 740-744, 1990

4 Kommoss F., "Steroid receptors in ovarian carcinoma : immunohistochemical determination may lead to new aspects" 47 : 317-322, 1992

5 Bizzi A., "Steroid receptors in epithelial ovarian carcinoma : relation to clinical parameters and survival" 48 : 6222-6226, 1988

6 Iversen OE., "Steroid receptor content in human ovarian tumors : survival of patients with ovarian carcinoma related to steroid receptor content" 23 : 65-76, 1986

7 Munstedt K., "Steroid hormone receptors and long term survival in invasive ovarian cancer" 89 : 1783-1791, 2000

8 Hogdall EV., "Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients : from the 'MALOVA' ovarian cancer study" 18 : 1051-1059, 2007

9 Yang XY., "Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients" 113 : 99-104, 2009

10 Rose PG., "Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer" 76 : 258-263, 1990

11 Hempling RE., "Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer" 21 : 447-451, 1998

12 Sevelda P., "Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma" 97 : 706-712, 1990

13 Serov, SF, "International histological classification and staging of tumors: histologic typing of ovarian tumors" World Health Organization 1973

14 Benedet JL., "FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology" 70 : 209-262, 2000

15 Tangjitgamol S., "Expressions of estrogen and progesterone receptors in epithelial ovarian cancer : a clinicopathologic study" 19 : 620-627, 2009

16 Lee P., "Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer" 96 : 671-677, 2005

17 Ho SM, "Estrogen, progesterone and epithelial ovarian cancer" 1 : 73-, 2003

18 Lindgren PR., "Estrogen and progesterone receptors in ovarian epithelial tumors" 221 : 97-104, 2004

19 Harding M., "Estrogen and progesterone receptors in ovarian cancer" 65 : 486-491, 1990

20 Geisler JP., "Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary" 60 : 424-427, 1996

21 Arias-Pulido H., "Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors" 114 : 480-485, 2009

22 Akahira J., "Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors" 93 : 807-815, 2002

23 Anderl P., "Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma" 25 : 135-140, 1988

24 Masood S., "Clinical correlation of hormone receptor status in epithelial ovarian cancer" 34 : 57-60, 1989

25 Schwartz PE., "Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers?" 68 : 751-758, 1986